We decided to retrospectively evaluate the use of 68Ga PSMA PET/CT to assess local control of bone and lymph node metastases in oligometastatic prostate cancer patients treated with SBRT in the current research. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.